BackKaleido Biosciences Overview

Kaleido Biosciences Total Assets

Track Kaleido Biosciences's total assets ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$0.00

Peer trimmed avg / median

Loading

Kaleido Biosciences Total Assets History

Loading

Kaleido Biosciences vs. peers: Total Assets Comparison

Loading

Kaleido Biosciences Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Kaleido Biosciences (KLDO) FAQ

As of the most recent data (September 2023), KLDO shows a total assets of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, KLDO's total assets is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Kaleido Biosciences is outperforming or lagging.

Tracking KLDO's total assets over time shows whether Kaleido Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total assets page, Stockcircle has Kaleido Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total assets (currently $0) with ownership activity and broader fundamentals.

Kaleido Biosciences's total assets is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.